Principal Investigator
Carl Landgren
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20230479
Clinical Trial Summary
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Myeloma
Contact Information
Phone Number
305-243-2647